medigraphic.com
ISSN 1561-3127 (Electronic)
ISSN 0864-3466 (Print)

2012, Number 2

<< Back Next >>

Revista Cubana de Salud Pública 2012; 38 (2)

The National Laboratory of Reference and its contribution to the elimination of tuberculosis in Cuba

Montoro CE, Díaz RR, Lemus MD, Mederos CL, Valdés HI, Martínez RMR, Llop HA, Valdivia ÁJA

Language: Spanish
References: 54
Page: 214-229
PDF size: 203.08 Kb.


ABSTRACT

The participation of the National Laboratory of Reference and Research on Tuberculosis and Mycobacteria of "Pedro Kouri" Institute of Tropical Medicine in the organization of the bacteriological resources for the diagnosis and screening of cases in the primary health care, in support of the national program for control of tuberculosis, was described in this paper. Reference was made to the functions and main scientific activities of this laboratory, which is a PAHO/WHO collaborating center at the forefront of the tuberculosis diagnosis laboratory network in the country. The introduction and the implementation of state-of-the-art technologies have allowed valuable tools to be used to meet several challenges posed by tuberculosis and mycobacteria nowadays. Thanks to the implementation of a World Fund against AIDS, tuberculosis and malaria project, the diagnosis network has strengthened, which must contribute to the elimination of tuberculosis as a health problem in Cuba in the near future.


REFERENCES

  1. Organización Panamericana de la Salud. Manual para el diagnóstico Bacteriológico de la Tuberculosis. Normas y Guía Técnica. Parte I Baciloscopía. Washington, D.C.: OPS; 2008.

  2. Valdivia JA, Jiménez CA, Ferrá C, Mederos L, Echemendía M, Mazón D. El Laboratorio Nacional de Referencia de Mycobacteria y Tuberculosis dentro de la lucha antituberculosa en Cuba. Rev Cubana Med Trop. 1988;40:51-66.

  3. Marrero A, Carreras L, Valdivia JA, Montoro E, González E, Torres R, et al. Programa Nacional de Control de la Tuberculosis. Manual de Normas y Procedimientos. La Habana: Editorial Ciencias Médicas; 1999.

  4. Martínez MR, García G, Sardiña M, Díaz M, Columbie V, Pequero R, et al. Introducción de nuevos métodos de control de calidad de baciloscopia de esputo BAAR, en el Laboratorio Nacional de Referencia del Instituto de Medicina Tropical ¨Pedro Kourí¨. Rev Cubana Med Trop [Internet]. 2007 [citado 30 Nov 2011]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0375-07602007000300013&lng=es

  5. Martínez MR, García G, Sardiña M, Díaz M, Columbie V, Pequero R, et al. Evaluación de nuevos métodos para el control de calidad de la baciloscopia de tuberculosis en Cuba. Rev Inst Nal Enf Resp Mex. 2008;21:99-106.

  6. Organización Panamericana de la Salud. Manual para el diagnóstico Bacteriológico de la Tuberculosis. Normas y Guía Técnica. Parte II Cultivo. Washington, D.C.: OPS; 2008.

  7. Sorlozano A, Soria I, Roman J, Huertas P, Soto MJ, Piedrola G, et al. Comparative evaluation of three culture methods for the isolation of mycobacteria from clinical samples. J Microbiol Biotechnol. 2009;19:1259-64.

  8. Werngren J, Klintz L, Hoffner SE. Evaluation of a novel kit for use with the BacT/ALERT 3D System for drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol. 2006;44:21302.

  9. Piersimoni C, Scarparo C, Callegaro A, Passerine Tosi C, Nista D, Bornigia S, et al. Comparison of MB/BacT ALERT 3D System with Radiometric BACTEC System and Lowenstein-Jensen Medium for recovery and identification of Mycobacteria from clinical specimens: a multicenter study. J Clin Microbiol. 2001;39:6517.

  10. Marzouk M, Kahla IB, Hannachi N, Ferjeni A, Ben Salma W, Ghezal S, et al. Evaluation of an immunochromatographic assay for rapid identification of Mycobacterium tuberculosis complex in clinical isolates. Diag Microbiol Infect Dis. 2011;69:3969.

  11. Gaillarda T, Fabreb M, Martinauda C, Vongb R, Brisoua P, Solerb Ch. Assessment of the SD Bioline Ag MPT64 Rapid™ and the MGIT™ TBc identification tests for the diagnosis of tuberculosis. Diag Microbiol Infect Dis. 2011;70:1546.

  12. Montoro E. Multiple drug resistance: a threat for tuberculosis control. Pan Am J Public Health. 2004;16:68-73.

  13. Migliori GB, Matteelli A, Cirillo D, Pai M. Diagnosis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: Current standards and challenges. Can J Infect Dis Med Microbiol. 2008;19:169-72.

  14. Valdivia JA, Suarez R. Incidencia y prevalencia de cepas drogorresistentes en el Hospital antituberculoso "Julio Trigo"de La Habana. Bol Hig Epidemiol. 1968;6:247-51.

  15. Valdivia JA, Jiménez C, Rodríguez R, Mederos L, Echemendía M, Valdés L, et al. Estudio cooperativo de la resistencia a las drogas antibacilares en cepas de M. tuberculosis aisladas en pacientes tuberculosos. (Informe preliminar). Rev Cubana Med Trop. 1982;34:119-25.

  16. Pablos Méndez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, et al. For the World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. Global surveillance for antituberculosis-drug resistance, 1994-1997. N Engl J Med. 1998;338:1641-9.

  17. World Health Organization-International Union against Tuberculosis and Lung Disease Global Project and Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world. Report No. 2 Prevalence and trends. Geneva: WHO; 2000.

  18. World Health Organization-International Union against Tuberculosis and Lung Disease. Global Project and Anti-Tuberculosis Drug Resistance Surveillance, 1999-2002. Third Global Project, 2004. Anti-tuberculosis drug resistance in the world. Geneva: WHO; 2000.

  19. World Health Organization-International Union against Tuberculosis and Lung Disease. Global Project and Anti-Tuberculosis Drug Resistance Surveillance, Fourth Global Project, 2008. Anti-tuberculosis drug resistance in the world. Geneva: WHO; 2008.

  20. Montoro E, Lemus D, Echemendía M, Armas L, González Ochoa E, Llanes MJ, et al. Drug-resistant tuberculosis in Cuba. Results of the three global projects. Tuberculosis. 2006;86:319-23.

  21. Lemus D, Martín A, Montoro E, Portaels F, Palomino JC. Rapid alternative methods for detection of rifampicin resistance in Mycobacterium tuberculosis. J Antimicob Chemother. 2004;54:130-3.

  22. Montoro E, Lemus D, Echemendía M, Martin A, Portaels F, Palomino JC. Comparative evaluation of the nitrate reduction assay, the MTT test and the resazurin microtitre assay for drug susceptibility testing of clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother. 2005;55:500-5.

  23. Yzquierdo SL, Lemus D, Echemendía M, Montoro E, McNerney R, Martin A, et al. Evaluation of phage assay for rapid phenotypic detection of rifampicin resistance in Mycobacterium tuberculosis. Ann Clin Microbiol Antimicrob. 2006;5:11.

  24. Lemus D, Montoro E, Echemendía M, Martin A, Portaels F, Palomino JC. Nitrate Reductase Assay for detection of drug resistance in Mycobacterium tuberculosis: simple and inexpensive method for low resources laboratories. J Med Microbiol. 2006;55:861-3.

  25. Mirabal N, Yzquierdo S, Lemus D, Madruga M, Milian Y, Echemendía M, et al. Evaluation of colorimetric methods using nicotinamide for rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis. J Clin Microbiol. 2010;48:2729-33.

  26. Leao SC, Martin A, Mejia GI, Palomino JC, Robledo J, Telles MA, Portaels F. Practical handbook for the phenotypic and genotypic identification of Mycobacteria. Brugge, Belgium: Vanden Broelle; 2004.

  27. Yzquierdo SL, Mederos LM, Díaz A, Echemendía M, Montoro E. Aplicación de RPC-PLFR en el diagnóstico de micobacterias no tuberculosas. Rev Chil Infect. 2007;24:391-6.

  28. Van Soolingen D. Molecular epidemiology of tuberculosis and other mycobacterial infections: main methodologies and achievements. J Inter Med. 2001;249:1-26.

  29. Behr MA, Mostowy S. Molecular tools for typing and branding the tubercle bacillus. Curr Mol Med. 2007;7:309-17.

  30. Van Embden JD, Cave MD, Crawford JT. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol. 1993;31:406-9.

  31. Kremer K, Arnold C, Cataldi A, Gutiérrez MC, Haas WH, Panaiotov S, et al. Discriminatory power and reproducibility of novel DNA typing methods for Mycobacterium tuberculosis complex strains. J Clin Microbiol. 2005;43:5628-38.

  32. Díaz R, de Haas P, Gómez RI, Marrero A, Cabanas M, Valdivia JA, et al. Molecular Epidemiology of Tuberculosis in Cuba, 1994-1995; Comparison of IS6110-RFLP and Spoligotyping. Int J Tuberc Lung Dis. 1998;2:743-50.

  33. Díaz R, Gómez RI, Restrepo E, Rumbaut R, Valdivia JA, Soolingen D. Transmission of tuberculosis in Havana, Cuba: a molecular epidemiological study by IS6110 Restriction fragment length polymorphism typing. Mem Inst Oswaldo Cruz. 2001; 96:437-43.

  34. Díaz R, Montoro E, González R, Echemendía M, Valdivia JA. Analysis of Mycobacterium tuberculosis strains isolated during an outbreak of HIV-infected patients by DNA fingerprinting. Am J Trop Med Hyg. 1995,53:S155-6.

  35. Díaz R, Gómez RI, García N, Valdivia JA, Soolingen D. Molecular epidemiology study on transmission of tuberculosis in a hospital for mentally handicapped patients in Havana, Cuba. J Hosp Infect. 2001;49:30-6.

  36. Díaz R, Crespo FM, Herrera S, Sevy Court J, Marrero A, Soolingen D. Laboratory cross-contamination of Mycobacterium tuberculosis during preparation of smears. Internet J Third World Med. 2005;2.

  37. Kremer K, van Soolingen D, Frothingham R, Hass WH, Hermans PWM, Martin C, et al. Comparison of methods based on different molecular epidemiological markers for typing of Mycobacterium tuberculosis complex strains: interlaboratory study of power of discrimination and reproducibility. J Clin Microbiol. 1999;37:2607-18.

  38. Kamerbeek J, Kock A, van Agterveld M, van Soolingen D, Kuijper S, Burshoten A. Rapid detection and simultaneous strain differentiation of Mycobacterium tuberculosis for diagnosis and tuberculosis control. J Clin Microbiol. 1997;35:907-14.

  39. Supply P, Allix C, Lesjean S, Cardoso Oelemann M, Rusgh Gerdes S, Willery E, et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol. 2006;44:4498-510.

  40. García de Viedma D, Mokrousov I, Rastogi N. Innovations in the molecular epidemiology of tuberculosis. Enferm Infec Microbiol Clin. 2011;29 (Suppl 1):8-13.

  41. Diaz R, González Y, Goza R, Lemus D, Montoro E. Genotyping of multidrug-resistant (MDR) Mycobacterium tuberculosis isolates from Cuba, 2000-2008. Int J Tuberc Lung Dis. 2009;13(12):S368.

  42. Diaz R, Goza R, Montoro E. Variable number tandem repeat typing of Mycobacterium tuberculosis isolates from Havana, Cuba. Int J Tuberc Lung Dis. 2011,15(11):S278.

  43. Valdivia JA, Suárez R, Echemendía M. Mycobacterium habana: probable nueva especie dentro de las micobacterias no clasificadas. Bol Hig Epidemiol. 1971;9:65-73.

  44. Mederos LM, Valdivia JA, Valero Guillén PL. Analysis of lipids reveals differences between Mycobacterium habana and Mycobacterium simiae. Microbiology. 1998;144:1181-8.

  45. Mederos LM, Valdivia JA, Valero Guillén PL. Lipids of ¨Mycobacterium habana¨, a synonym of Mycobacterium simiae with vacontrol de la calidadine potencial. Tuberculosis. 2006;86:324-9.

  46. Mederos LM, Valdivia JA, Valero-Guillén PL. Analysis of the structure of mycolic acids of Mycobacterium simiae reveals a particular composition of alpha-mycolates in strain `M. habana' TMC 5135, considered as immunogenic in tuberculosis and leprosy. Microbiology. 2007;153:4159-65.

  47. Mederos LM, Valdivia JA, Valero Guillén PL. New variants of polar glycopeptidolipids detected in Mycobacterium simiae including ´M. habana´ strains, as evidence by electrospray ionization-ion trap-mass spectrometry. J Appl Microbiol. 2008;105:602-14.

  48. Valdivia JA, Ferrá C, Echemendía M. Estudio de 16 cepas de Micobacterias cromogénicas y de crecimiento rápido. Rev Cubana Med Trop. 1975;27:213-23.

  49. Valdivia JA, Echemendía M, Inerarity M. Mycobacterium cubense: nueva especie pigmentada y de crecimiento lento. Rev Cubana Med Trop. 1979;31:85-8.

  50. Gupta HP, Singh NB, Mathur IS, Gupta SK. ´Mycobacterium habana´ a new immunogenic strain in experimental tuberculosis of mice. Ind J Exp Biol. 1979;17:1190.

  51. World Health Organization. Report of the 3th Anual Immnunology (IMLEP) and Chemotherapy (THELEP) of Leprosy, Molecular Biology, Subcommitte (BIOLEP). Geneva: WHO; 1989.

  52. Hernández Pando R, Orozco H, Arriaga K, Sampieri A, Larriva Sahd J, Madrid Marina V. Analysis of the local kinetics and localization of interleukin-1 alpha, tumour necrosis factor-a and transforming growth factor-b, during the course of experimental pulmonary tuberculosis. Immunology. 1997;90:60717.

  53. Valdés, I, Echemendía M, Mederos L, Valdivia JA, Montoro E. Aspectos relevantes del uso de Mycobacterium habana como candidato vacunal contra la tuberculosis. Vaccimonitor. 2011;20(3):34-9.

  54. Divya JM, Garg SK, Singh NB. Mechanisms involved in protective immune response generated by secretory proteins of Mycobacterium habana against experimental tuberculosis. Scand J Immunol. 2000;51:502-10.




2020     |     www.medigraphic.com